University of Galway has conferred honorary Doctorates of Science upon Professor Paul Yock and Dr Josh Makower, founders of Stanford Biodesign.
This recognition celebrates their groundbreaking contributions to medical technology innovation and their pivotal role in shaping the transformative partnership between Stanford Biodesign and BioInnovate Ireland, a flagship programme at the University of Galway.
As one of the world’s top five medtech hubs, Galway owes much of its prominence to the synergy between BioInnovate and Stanford Biodesign.
This partnership has driven advancements in healthcare innovation, strengthened Galway’s position on the global stage, and fostered a thriving ecosystem where Irish startups flourish alongside leading multinationals.
Since its establishment in 2011, with the support of Enterprise Ireland, BioInnovate Ireland has championed the Stanford Biodesign process, a globally renowned framework for identifying and solving healthcare challenges.
As the only European affiliate of Stanford Biodesign since 2013, BioInnovate Ireland underscores Galway’s leadership in medtech innovation.
Reflecting on this legacy, Professor Mark Bruzzi, Founder and Non-Executive Director of BioInnovate said. “Bringing the Biodesign process to Galway anchored our medtech sector, creating a launchpad for innovative Irish startups and inspiring global collaboration. Paul and Josh have been instrumental in this journey.”
“Professor Martin O’Halloran, Executive Director of BioInnovate added “Their influence is felt not just in the groundbreaking technologies they have developed, but also in the mentorship and generosity that continue to shape Ireland’s medtech landscape. Their honorary doctorates are a fitting tribute to their global impact.”
Over the last 13 years, BioInnvoate has led to 33 start-ups, and 1 in 4 of these are led by female founders.
Professor Yock and Dr. Makower exemplify global leadership in medtech innovation. Since 2024, BioInnovate is supported by the Innovators’ Initiative Programme, co-funded by the Government of Ireland and the European Union through the Northern and Western Regional Programme 2021-2027.
Through this programme, BioInnovate Ireland continues to lead the way in developing life-changing healthcare solutions.
Galway’s collaboration with Stanford Biodesign exemplifies the power of global partnerships to drive innovation, improve patient outcomes, and inspire the next generation of health technology leaders.
